國立虎尾科技大學 |

Resistance to Targeted Therapies in Multiple Myeloma

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Resistance to Targeted Therapies in Multiple Myeloma/ edited by Silvia CW Ling, Steven Trieu.
其他作者:	Trieu, Steven.
面頁冊數:	XVII, 154 p. 5 illus.online resource. :
Contained By:	Springer Nature eBook
標題:	Cancer Research. -
電子資源:	https://doi.org/10.1007/978-3-030-73440-4
ISBN:	9783030734404

Resistance to Targeted Therapies in Multiple Myeloma
Resistance to Targeted Therapies in Multiple Myeloma[electronic resource] /edited by Silvia CW Ling, Steven Trieu. - 1st ed. 2021. - XVII, 154 p. 5 illus.online resource. - Resistance to Targeted Anti-Cancer Therapeutics,222196-551X ;. - Resistance to Targeted Anti-Cancer Therapeutics,4.

1. The role of targeted therapy in multiple myeloma -- 2. Lenalidomide -- 3. Pomalidomide -- 4. Mechanisms driving resistance to proteasome inhibitors bortezomib, carfilzomib and ixazomib in multiple myeloma -- 5. Daratumumab -- 6. Elotuzumab -- 7. Histone deacetylase inhibitors -- 8. Bone targeted therapies -- 9. New targeted therapies for multiple myeloma under clinical investigation.

Multiple Myeloma remains an incurable malignancy. As the disease progresses, it invariably becomes resistant to treatment and almost all patients develop refractory disease. There are multiple different types of targeted therapies and many of them are used in combination at different stages of disease. Targeted therapies that are approved to be used include Proteasome Inhibitors, Immunomodulatory Drugs and Monoclonal Antibodies. Second and third generations of these drugs are developed to overcome resistance and they have unique mechanism of actions. Targeted therapies that are undergoing clinical trials include CAR-T cells, bi-specific antibodies, vaccines, ubiquitin ligase inhibitors and BCL-2 inhibitors. This book will help to develop an understanding of targeted therapies in Multiple Myeloma. Its goal is to provide a unique review of the mechanism of action and resistance of the many targeted therapies in Multiple Myeloma by leaders of the field. The book will be useful for students in medical science, clinicians, health professionals, scientists, pharmaceutical professionals, drug developers, and policy makers. This book will provide an insightful knowledge of the biology of Multiple Myeloma, the mechanism of action and resistance of targeted therapies, application of biomarkers and genomics and possible strategies in overcoming resistance and future development.

ISBN: 9783030734404

Standard No.: 10.1007/978-3-030-73440-4doiSubjects--Topical Terms:

668358
Cancer Research.

LC Class. No.: RC261-271

Dewey Class. No.: 614.5999

Resistance to Targeted Therapies in Multiple Myeloma
LDR:03229nam a22004095i 4500 001 1049418
003 DE-He213
005 20210815072851.0
007 cr nn 008mamaa
008 220103s2021 sz | s |||| 0|eng d
020 $a 9783030734404 $9 978-3-030-73440-4
024 7 $a 10.1007/978-3-030-73440-4 $2 doi
035 $a 978-3-030-73440-4
050 4 $a RC261-271
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 614.5999 $2 23
245 1 0 $a Resistance to Targeted Therapies in Multiple Myeloma $h [electronic resource] / $c edited by Silvia CW Ling, Steven Trieu.
250 $a 1st ed. 2021.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2021.
300 $a XVII, 154 p. 5 illus. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Resistance to Targeted Anti-Cancer Therapeutics, $x 2196-551X ; $v 22
505 0 $a 1. The role of targeted therapy in multiple myeloma -- 2. Lenalidomide -- 3. Pomalidomide -- 4. Mechanisms driving resistance to proteasome inhibitors bortezomib, carfilzomib and ixazomib in multiple myeloma -- 5. Daratumumab -- 6. Elotuzumab -- 7. Histone deacetylase inhibitors -- 8. Bone targeted therapies -- 9. New targeted therapies for multiple myeloma under clinical investigation.
520 $a Multiple Myeloma remains an incurable malignancy. As the disease progresses, it invariably becomes resistant to treatment and almost all patients develop refractory disease. There are multiple different types of targeted therapies and many of them are used in combination at different stages of disease. Targeted therapies that are approved to be used include Proteasome Inhibitors, Immunomodulatory Drugs and Monoclonal Antibodies. Second and third generations of these drugs are developed to overcome resistance and they have unique mechanism of actions. Targeted therapies that are undergoing clinical trials include CAR-T cells, bi-specific antibodies, vaccines, ubiquitin ligase inhibitors and BCL-2 inhibitors. This book will help to develop an understanding of targeted therapies in Multiple Myeloma. Its goal is to provide a unique review of the mechanism of action and resistance of the many targeted therapies in Multiple Myeloma by leaders of the field. The book will be useful for students in medical science, clinicians, health professionals, scientists, pharmaceutical professionals, drug developers, and policy makers. This book will provide an insightful knowledge of the biology of Multiple Myeloma, the mechanism of action and resistance of targeted therapies, application of biomarkers and genomics and possible strategies in overcoming resistance and future development.
650 1 4 $a Cancer Research. $3 668358
650 0 $a Immunology. $3 592892
650 0 $a Cancer research. $3 1253664
700 1 $a Trieu, Steven. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1353541
700 1 $a Ling, Silvia CW. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1353540
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783030734398
776 0 8 $i Printed edition: $z 9783030734411
776 0 8 $i Printed edition: $z 9783030734428
830 0 $a Resistance to Targeted Anti-Cancer Therapeutics, $x 2196-5501 ; $v 4 $3 1254768
856 4 0 $u https://doi.org/10.1007/978-3-030-73440-4
912 $a ZDB-2-SBL
912 $a ZDB-2-SXB
950 $a Biomedical and Life Sciences (SpringerNature-11642)
950 $a Biomedical and Life Sciences (R0) (SpringerNature-43708)